TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9236626

Group type: EXPERIMENTAL
Intervention: Mild diabetic polyneuropathy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Other polyneuropathies
Number of subjects: 47

Group type: COMPARATOR
Intervention: Vasculitic polyneuropathy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Severe diabetic polyneuropathy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mild diabetic polyneuropathy (10 patients)
Number of subjects: 47
Study: 7864906

Group type: EXPERIMENTAL
Intervention: Paracentesis through a sideport incision
Number of subjects: 28

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 28
Study: 3118342

Group type: EXPERIMENTAL
Intervention: Combined fast neutron and photon irradiation (mixed-beam)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional photon irradiation alone
Number of subjects: 91
Study: 29513132

Group type: EXPERIMENTAL
Intervention: Focused Playtime Intervention (FPI) for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Active control intervention
Number of subjects: 70
Study: 27020071

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Enhanced Medical Care (EMC)
Number of subjects: 106
Study: 25276762

Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 22738947

Group type: EXPERIMENTAL
Intervention: Low O2 saturation target range (85%-89%)
Number of subjects: 115

Group type: COMPARATOR
Intervention: High O2 saturation target range (91%-95%)
Number of subjects: 115
Study: 20608357

Group type: EXPERIMENTAL
Intervention: Indwelling anterior urethral stent
Number of subjects: 38

Group type: COMPARATOR
Intervention: Urethral dilatation
Number of subjects: 38
Study: 18452257

Group type: EXPERIMENTAL
Intervention: Lowering the fasting plasma glucose (FPG) criteria for IFG from 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL)
Number of subjects: 7211

Group type: EXPERIMENTAL
Intervention: Lowering the FPG criterion for IFG
Number of subjects: 7211

Group type: EXPERIMENTAL
Intervention: Subjects with IFG (5.6‐7.0 mmol/L)
Number of subjects: 7211

Group type: EXPERIMENTAL
Intervention: Subjects with normal glucose tolerance (NGT)
Number of subjects: 7211

Group type: EXPERIMENTAL
Intervention: Baseline FPG for predicting the development of diabetes
Number of subjects: 7211
Study: 15845691

Group type: EXPERIMENTAL
Intervention: DM-TEA (Dextromethorphan 40 mg IM combined with TEA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPM-TEA (Chlorpheniramine maleate 20 mg combined with TEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CPM-GA (Chlorpheniramine maleate 20 mg with general anesthesia)
Number of subjects: 0
Study: 12425755

Group type: EXPERIMENTAL
Intervention: G‐CSF 5 microg/kg subcutaneously daily
Number of subjects: 413

Group type: COMPARATOR
Intervention: leridistim 5 microg/kg subcutaneously daily
Number of subjects: 413

Group type: COMPARATOR
Intervention: leridistim 10 microg/kg subcutaneously every other day alternating with placebo
Number of subjects: 413
Study: 10509850

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 (0.8% polymer concentration)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lower-molecular-weight hyaluronan (LMW HA) (1% polymer concentration)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20
Number of subjects: 70

Group type: COMPARATOR
Intervention: Lower-molecular-weight hyaluronan (LMW HA)
Number of subjects: 70
Study: 7571793

Group type: EXPERIMENTAL
Intervention: Graduated compression stockings
Number of subjects: 0

Group type: COMPARATOR
Intervention: O-(beta-hydroxyethyl)-rutosides (HR)
Number of subjects: 0
Study: 1857137

Group type: EXPERIMENTAL
Intervention: Randomized primary care system
Number of subjects: 0
Study: 6140700

Group type: EXPERIMENTAL
Intervention: DL‐308 (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: DL‐308 (20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: oxazepam (30 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30736085

Group type: EXPERIMENTAL
Intervention: CT-guided Radiofrequency Sacroplasty (RFS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cement Sacroplasty (CSP)
Number of subjects: 100
Study: 29800026

Group type: EXPERIMENTAL
Intervention: Sirolimus gel, 0.2%
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 26999197

Group type: EXPERIMENTAL
Intervention: Raw Tomatoes (RT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tomato Sauce (TS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tomato Sauce with Olive Oil (TSOO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Sugar solution)
Number of subjects: 40
Study: 23878109

Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora (350 mg) three times daily for two weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Scutellaria lateriflora (350 mg)
Number of subjects: 43
Study: 22158682

Group type: EXPERIMENTAL
Intervention: Sabin IPV (high D Ag)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sabin IPV (middle D Ag)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Sabin IPV (low D Ag)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Trivalent OPV (control)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional IPV (cIPV, control)
Number of subjects: 500
Study: 21702264

Group type: EXPERIMENTAL
Intervention: Anti HCV positive by ELISA
Number of subjects: 254
Study: 17286522

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 1460

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 1460
Study: 15926987

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 51

Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 51
Study: 12480850

Group type: EXPERIMENTAL
Intervention: Self help intervention (five self help booklets)
Number of subjects: 1527

Group type: COMPARATOR
Intervention: Normal care (control group)
Number of subjects: 1527

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1527
Study: 9704834

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 0.05% cream once daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Clobetasone butyrate 0.05% cream twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both treatments (FP and CB)
Number of subjects: 22
Study: 9345395

Group type: EXPERIMENTAL
Intervention: 3 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 9 MIU of recombinant human IFN‐beta (r‐hIFN‐beta) self-administered by subcutaneous injection three times a week for 6 months
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 2565767

Group type: EXPERIMENTAL
Intervention: Alpidem (150 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 348406

Group type: EXPERIMENTAL
Intervention: Hydrocortisone valerate cream (0.2 percent)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Fluorinated beta-methasone valerate cream (0.1 percent)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hydrocortisone cream (0.1 percent)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo cream base
Number of subjects: 68
Study: 27522059

Group type: EXPERIMENTAL
Intervention: Combined inflammation z-score
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Pentraxin 3
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Serum amyloid P
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Endothelin-1
Number of subjects: 1159

Group type: EXPERIMENTAL
Intervention: Interleukin-2
Number of subjects: 1159
Study: 25557807

Group type: EXPERIMENTAL
Intervention: Lifestyle-based weight loss program
Number of subjects: 234
Study: 24371452

Group type: EXPERIMENTAL
Intervention: SuperUlam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21645117

Group type: EXPERIMENTAL
Intervention: Active cellulose powder
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 19588513

Group type: EXPERIMENTAL
Intervention: Pretreatment assessment including self‐report questionnaires, interviews, and psychophysiological assessment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pretreatment assessment
Number of subjects: 100
Study: 17215608

Group type: EXPERIMENTAL
Intervention: Brisk walking program (9 women)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Brisk walking plus diet program (10 women)
Number of subjects: 19
Study: 12768510

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 186

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 186
Study: 11079660

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 9348547

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Medication-free phase
Number of subjects: 14
Study: 8406169

Group type: EXPERIMENTAL
Intervention: Low dose ursodeoxycholic acid
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: COMPARATOR
Intervention: High fibre, low refined carbohydrate diet
Number of subjects: 93
Study: 3465375

Group type: EXPERIMENTAL
Intervention: Intravenous Prostaglandin F2-alpha
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Extra-amniotic Prostaglandin F2-alpha
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intramuscular Prostaglandin F2-alpha
Number of subjects: 45
Study: 31447383

Group type: EXPERIMENTAL
Intervention: IIEF-5 score
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: AMS score
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Age group 61-70
Number of subjects: 248
Study: 30249630

Group type: EXPERIMENTAL
Intervention: Initial triple combination therapy with metformin, dapagliflozin, and saxagliptin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional stepwise add-on therapy
Number of subjects: 104
Study: 26767508

Group type: EXPERIMENTAL
Intervention: 4 Pillars Immunization Toolkit, early delivery of donated vaccine, staff education, feedback on progress
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study: 25162257

Group type: EXPERIMENTAL
Intervention: Web-based lifestyle program (Balance after Baby)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 22577186

Group type: EXPERIMENTAL
Intervention: Circuit training
Number of subjects: 250

Group type: COMPARATOR
Intervention: Usual physiotherapy (control)
Number of subjects: 250
Study: 20697276

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (0.3% gatifloxacin ophthalmic solution)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moxifloxacin (0.5% moxifloxacin hydrochloride ophthalmic solution)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 44

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 44
Study: 18443573

Group type: EXPERIMENTAL
Intervention: D2 (4 mg/1.25 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: D1 (2 mg/0.625 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15977465

Group type: COMPARATOR
Intervention: Alendronate (5 mg daily)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alendronate plus whole-body vibration exercise (ALN+EX)
Number of subjects: 50
Study: 14534616

Group type: EXPERIMENTAL
Intervention: GSTP1‐Ile105/Val105 genotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygotes for GSTP1 alleles
Number of subjects: 0
Study: 10551504

Group type: EXPERIMENTAL
Intervention: Chronic electrical stimulation
Number of subjects: 4
Study: 8676225

Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 19

Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 19
Study: 1852179

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (surgical treatment)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Optimal medical care (control group)
Number of subjects: 659
Study: 6822050

Group type: EXPERIMENTAL
Intervention: Eccentric muscle contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concentric muscle contractions
Number of subjects: 0
Study: 31955956

Group type: EXPERIMENTAL
Intervention: Hypokalemia (<3.0mEq/L)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Hyperkalemia (>6.0mEq/L)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normokalemia (3.5-5mEq/L)
Number of subjects: 200
Study: 31371391

Group type: EXPERIMENTAL
Intervention: Stochastic self-assembly process for ion channel clustering; model parameters include nucleation, growth, and removal probabilities; specific channels studied include CaV1.2, CaV1.3, BK, and TRPV4.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer model simulations of channel delivery to membrane; channels delivered at randomly assigned locations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-regulating feedback mechanism incorporated in the model.
Number of subjects: 0
Study: 28906561

Group type: EXPERIMENTAL
Intervention: Intravenous rolapitant (166.5 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Oral rolapitant (180 mg)
Number of subjects: 123
Study: 25600484

Group type: EXPERIMENTAL
Intervention: Vitaminized olive oil (VitVOO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo olive oil (PlaVOO)
Number of subjects: 60
Study: 24332466

Group type: EXPERIMENTAL
Intervention: Dynamic Hip Screw (DHS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: External Fixator
Number of subjects: 60
Study: 22505800

Group type: EXPERIMENTAL
Intervention: Acyclovir (N = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No acyclovir (Control, N = 30)
Number of subjects: 60
Study: 19120077

Group type: EXPERIMENTAL
Intervention: Standard-dose tacrolimus (target trough levels >10 ng/mL) and corticosteroids; n = 183
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 2g/day, reduced-dose tacrolimus (target trough levels </=8 ng/mL), and corticosteroids; n = 170
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Daclizumab induction, MMF, reduced-dose tacrolimus delayed until the fifth day posttransplant, and corticosteroids; n = 172
Number of subjects: 525
Study: 16881381

Group type: COMPARATOR
Intervention: Oral hormone therapy (HT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Percutaneous gel
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Reservoir patch
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Matrix patch
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Gel
Number of subjects: 88
Study: 15566133

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26
Study: 11342892

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, aspirin, and ranitidine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9386999

Group type: EXPERIMENTAL
Intervention: Neuroticism
Number of subjects: 5279

Group type: EXPERIMENTAL
Intervention: Mastery
Number of subjects: 5279

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 5279

Group type: COMPARATOR
Intervention: Medical morbidity and age
Number of subjects: 5279
Study: 7947564

Group type: EXPERIMENTAL
Intervention: Secretor status (determined from saliva samples using a haemagglutination technique)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (age and sex matched individuals without oral cancer)
Number of subjects: 200
Study: 3214944

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 7) increased breastfeeding frequency by 50% after the second menstruation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 7) maintained spontaneous feeding pattern
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Experimental group (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 14
Study: 31595303

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 0
Study: 30724760

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients using simple analgesics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients using centrally acting analgesics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Medication-overuse headache (MOH) patients classified as DSM-IV substance dependent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SDS scores in MOH patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SDS scores predicting successful withdrawal
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: ROC analysis of SDS scores
Number of subjects: 100
Study: 27530911

Group type: EXPERIMENTAL
Intervention: Gastric Bypass (GBP)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 38
Study: 24906295

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study: 23279557

Group type: EXPERIMENTAL
Intervention: Higher protein diet (HP): 32% protein, 41% carbohydrate, 25% fat
Number of subjects: 71

Group type: COMPARATOR
Intervention: Higher carbohydrate diet (HC): 20% protein, 58% carbohydrate, 21% fat
Number of subjects: 71
Study: 21966393

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg/d; n = 105)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo treatment (n = 111)
Number of subjects: 216
Study: 18838842

Group type: EXPERIMENTAL
Intervention: Pre-exercise hyperhydration (26 ml of water x kg body mass(‐1) with 1.2 g glycerol x kg body mass(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Pre-exercise euhydration
Number of subjects: 6
Study: 16808678

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Brimonidine Purite 0.15%
Number of subjects: 106

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 106
Study: 15118290

Group type: EXPERIMENTAL
Intervention: Minimally-diluted BCP supplemented with potassium and magnesium (Group M)
Number of subjects: 70
Study: 11866251

Group type: EXPERIMENTAL
Intervention: Methadone dose reduction with decrease instruction
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methadone dose decrease
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methadone maintenance dose
Number of subjects: 18
Study: 9834304

Group type: EXPERIMENTAL
Intervention: Intracoronary stenting with a Palmaz‐Schatz stent
Number of subjects: 383

Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 383
Study: 8948744

Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with morphine 4 mg and bupivacaine 0.125% 100 ml
Number of subjects: 50

Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCA) with morphine 30 mg and ketorolac 90 mg in 100 ml of saline
Number of subjects: 50
Study: 2509059

Group type: EXPERIMENTAL
Intervention: Tuberculin test using RT-23 2 T.U. with Tween 80
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitin test prepared from Mycobacterium intracellulare and Mycobacterium kansasii
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tuberculin reactions to 2 T.U. RT-23 or 5 T.U. P.P.D.
Number of subjects: 0
Study: 15943220

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg once daily for 8 weeks
Number of subjects: 114

Group type: COMPARATOR
Intervention: Olmesartan 20 mg once daily for 8 weeks
Number of subjects: 114
Study: 29962366

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard community treatment
Number of subjects: 60
Study: 28486559

Group type: EXPERIMENTAL
Intervention: Online mindfulness training
Number of subjects: 324

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 324
Study: 25994245

Group type: EXPERIMENTAL
Intervention: Coopdech® laryngoscope
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: CoPilot® laryngoscope
Number of subjects: 107

Group type: COMPARATOR
Intervention: Intubrite® laryngoscope
Number of subjects: 107

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 107
Study: 23453112

Group type: EXPERIMENTAL
Intervention: Open cell stent
Number of subjects: 223

Group type: COMPARATOR
Intervention: Closed cell stent
Number of subjects: 223
Study: 22106080

Group type: EXPERIMENTAL
Intervention: Visual aid
Number of subjects: 89

Group type: COMPARATOR
Intervention: No visual aid
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Higher literacy levels
Number of subjects: 89
Study: 19561485

Group type: EXPERIMENTAL
Intervention: Restricted fluid regimen
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard fluid regimen
Number of subjects: 22
Study: 16690590

Group type: EXPERIMENTAL
Intervention: Low folic acid diet (0 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal folic acid diet (2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High folic acid diet (40 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (800 microg/day) in humans
Number of subjects: 0
Study: 15364642

Group type: EXPERIMENTAL
Intervention: Aesculus hippocastanum tablets (Aesculaforce 50mg), taken twice daily for 8 weeks.
Number of subjects: 91
Study: 11371793

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 169

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 169
Study: 9413588

Group type: EXPERIMENTAL
Intervention: Shoe lift of 1.25 cm added to the left leg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correction of limb length discrepancy
Number of subjects: 20
Study: 8422221

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75